Article: Potential innovative targets in the treatment of pain: Combined µ and NOP receptor agonists.
2021 Volume 17, Issue 4, Page(s) 277–283
Abstract: Opioid analgesics are potent and widely used medications employed to manage moderate-to-severe acute pain; their utility in the management of chronic inflammatory and neuropathic pain is modest and is beset with adverse effects and concerns related to ... ...
Abstract | Opioid analgesics are potent and widely used medications employed to manage moderate-to-severe acute pain; their utility in the management of chronic inflammatory and neuropathic pain is modest and is beset with adverse effects and concerns related to abuse and addiction. The discovery of the nonclassical opioid, ie, the nociception/orphanin receptor (NOP), has sparked interest into another possible analgesic target. Preclinical studies have demonstrated pain mitigating effects associated with NOP receptor activation while simultaneously reducing conventional µ-opioid-related ad-verse and euphoric effects. Consequently, agents possessing dual agonism of both µ and NOP receptor activations present an innovative and promising potential target for pain management. |
---|---|
Language | English |
Publishing date | 2021-09-16 |
Publishing country | United States |
Document type | Journal Article |
ZDB-ID | 2397614-7 |
ISSN | 1551-7489 |
ISSN | 1551-7489 |
DOI | 10.5055/jom.2021.0659 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6563: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.